Journal: Stem cells (Dayton, Ohio)

Article Title: Defined human pluripotent stem cell culture enables highly efficient neuroepithelium derivation without small molecule inhibitors.

doi: 10.1002/stem.1622

Figure Lengend Snippet: Figure 1. Differentiation of human pluripotent stem cells to neuroepithelium under defined conditions. (A): Experimental timeline. (B): Reverse transcriptase polymerase chain reaction analysis of pluripotency, mesoderm, endoderm, and neuroectoderm gene expres- sion in differentiating H9 human embryonic stem cells (hESCs). “SB” indicates addition of SB431542 and “N” indicates addition of nog- gin. (C): Flow cytometry analysis of Pax6. Data are presented as mean 6 SD calculated from at least two biological replicates. Differentiation was conducted on Matrigel-coated substrates unless otherwise specified. (D): Images of neural rosette formation on day 6 of H9 hESC differentiation. The inset shows the magnified rosette structure. All images are of cells differentiated on Matrigel- coated substrates except for the one labeled “E6 (VTN-NC),” which indicates cells differentiated in E6 medium on substrates coated with recombinant vitronectin peptide. Scale bars in Pax6/N-cadherin-stained images are 250 mm; scale bars in Otx2/Sox2-stained images are 50 mm. (E): Representative flow cytometry histograms of N-cadherin, Otx2, and Sox2 expression at day 6 of differentiating H9 hESCs in E6 medium. Data are representative of two biological replicates and mean 6 SD are listed in Results. Gray histogram, IgG control; red histogram, label of interest. (F): Progression of Sox1 expression in E6/FI conditions with and without retinoic acid. Scale bars 5 100 mm.

Article Snippet: The following morning, cells were changed to E6 medium, E6 containing 10 mM SB431542 (Cellagentech, San Diego, CA (www.cellagen tech.com)), or E6 containing 10 mM SB431542 and 200 ng/ml recombinant human noggin (R&D Systems) to initiate differentiation.

Techniques: Reverse Transcription, Polymerase Chain Reaction, Flow Cytometry, Labeling, Recombinant, Staining, Cytometry, Expressing, Control

Journal: Cell Reports Medicine

Article Title: An Automated Organoid Platform with Inter-organoid Homogeneity and Inter-patient Heterogeneity

doi: 10.1016/j.xcrm.2020.100161

Figure Lengend Snippet:

Article Snippet: Noggin (Human) , MCE , Cat# HY-P7051A.

Techniques: Recombinant, Red Blood Cell Lysis, Viability Assay, Sequencing, Software, Injection

Journal: Scientific Reports

Article Title: Noggin promotes osteogenesis in human adipose-derived mesenchymal stem cells via FGFR2/Src/Akt and ERK signaling pathway

doi: 10.1038/s41598-024-56858-w

Figure Lengend Snippet: Noggin protein increases alkaline phosphatase (ALP) activity and early osteogenic genes expression in adult human mesenchymal stem cells from different tissues. Alkaline phosphatase (ALP) activity after 7-d culture of ( a ) normal human bone marrow stromal cells (BMSCs), ( b ) normal human dental pulp stem cells (DPSCs) and ( c ) human immortalized adipose-derived stem cell line (ASC52telo). Cells were treated with either 100 ng/ml recombinant human Noggin (NOG) or 100 ng/ml recombinant human bone morphogenetic protein 2 (BMP-2), or both (BMP-2 + NOG), in osteogenic medium containing ascorbic acid (Asc) and dexamethasone (Dex). ( d ) ALP activity after 7-d culture of ASC52telo cells in osteogenic medium with different Noggin doses (100–400 ng/ml). ( a–d ) Control represents cells maintained in standard growth medium. Relative mRNA levels (qPCR) of selected osteoblastic markers in ( e ) normal human ASCs and ( f ) normal human BMSCs continuously treated with Noggin (NOG) or BMP-2 for 7 days in osteogenic medium. Relative quantification to control cells cultured in osteogenic medium. ( a–f ) Average values ± SD are plotted. One-way ANOVA tests, * p < 0.05, ** p < 0.001, *** p < 0.0001, ns—not significant, relative to respective control or between marked groups.

Article Snippet: Recombinant human Noggin (rhNoggin, Origene) or recombinant human BMP-2 (rhBMP-2, ThermoFisher Scientific) were added from day 1 cultures at concentrations of 100 ng/ml, unless indicated otherwise.

Techniques: Activity Assay, Expressing, Derivative Assay, Recombinant, Control, Cell Culture